Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on ω Transaminase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel recombinant (R)-ω-transaminase mutant enables high-yield sitagliptin production with superior stereoselectivity and enzyme activity for pharmaceutical supply chains.
Patent CN116064451B reveals high-activity transaminase mutant. Enables cost reduction in pharmaceutical intermediates manufacturing with scalable enzymatic processes.
Patent CN111411095B discloses a novel recombinant (R)-ω-transaminase mutant with high activity and stereoselectivity for efficient sitagliptin intermediate production, ensuring supply chain stability.
Novel (R)-ω-transaminase mutant enables high-conversion synthesis of Sitagliptin intermediates, offering cost-effective and scalable pharmaceutical manufacturing solutions.
Patent CN111411094B discloses a novel mutant enzyme achieving 95.4% conversion at high substrate concentrations, offering significant cost reduction in API manufacturing.
Patent CN115896060A reveals a novel ω-transaminase mutant for silodosin synthesis, offering >99% ee and scalable biocatalysis for reliable supply chains.